Recombinant Anti-human CD33 VHH Single Domain Antibody (CAT#: NAB-321-sdAb)

• Promising results
  The results with the Recombinant Anti-human CD33 VHH Single Domain Antibody have been very promising. The leukemic cell counts have significantly decreased, and the side effects are minimal.
• Excellent for ELISA
  I've been using the antibody in my laboratory for ELISA tests, and it's been a game-changer. The binding affinity and specificity for human CD33 molecule are excellent.
• High specificity and low background for IA
  The recombinant Anti-human CD33 VHH Single Domain Antibody exceeded our expectations. The high specificity and low background have significantly improved the quality of our immunoassays.

1. Q 1: What is the Recombinant Anti-human CD33 VHH Single Domain Antibody's major application?

   A: The primary use of the Recombinant Anti-human CD33 VHH Single Domain Antibody is to target and treat acute myeloid leukemia (AML) by binding specifically to the CD33 antigen on leukemic cells, facilitating their identification and destruction by the immune system, while sparing healthy cells.

2. Q 2: Does the Recombinant Anti-human CD33 VHH Single Domain Antibody have any contraindications when used?

   A: Contraindications may include individuals with known hypersensitivity to any components of the antibody formulation. It should also be used with caution in patients with severe pre-existing conditions that could be exacerbated by the treatment. Consulting a healthcare provider is essential to assess individual suitability.

3. Q 3: How is harm to healthy cells reduced by the Recombinant Anti-human CD33 VHH Single Domain Antibody?

   A: The antibody's small size and specificity for the CD33 antigen allow it to bind only to leukemic cells, sparing most healthy cells. This specificity reduces the broad, systemic toxicity commonly associated with traditional treatments, resulting in fewer and less severe side effects.

View the frequently asked questions answered by Creative Biolabs Support.